Nebicur (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebicur, is a beta blocker presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Nebicur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol Hydrochloride is a selective β1‑adrenergic blocker indicated for conditions that involve elevated blood pressure or impaired cardiac function.

Hypertension: lowers systolic and diastolic pressure by reducing cardiac output and peripheral vascular resistance. Heart failure: improves left‑ventricular ejection fraction and reduces symptoms in patients with reduced‑ejection‑fraction heart failure.

Nebivolol Hydrochloride may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nausea or mild gastrointestinal upset. - Nasal congestion or rhinorrhoea.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Marked hypotension leading to syncope. - Bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Hepatic enzyme elevations or liver injury. - Worsening heart failure symptoms.

Before initiating Nebivolol Hydrochloride, clinicians should consider several safety aspects.

Monitor blood pressure: verify adequate control and avoid excessive hypotension. Assess cardiac function: evaluate baseline heart rate and conduction abnormalities. Use caution in asthma/COPD: β‑blockade may precipitate bronchospasm. Review concomitant beta‑blockers: avoid additive negative‑chronotropic effects. Adjust in renal/hepatic impairment: dose may need modification in severe dysfunction. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and AV‑node depression. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): increased risk of heart block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): may raise nebivolol plasma levels. - Clonidine abrupt withdrawal: can cause rebound hypertension. - Antihypertensive agents that cause profound vasodilation (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension. - Antidiabetic drugs: beta‑blockade can mask hypoglycaemia symptoms. - NSAIDs: may reduce antihypertensive efficacy. - Antidepressants (serotonergic agents): monitor for additive dizziness. - Digoxin: monitor for bradycardia when combined.